Crizotinib, an ALK inhibitor, is very effective in treating patients with advanced ALK-positive NSCLC, with an objective response rate of about 60% and a median progression-free survival of 8 to 10 months (Kwak et al. 2010; Shaw et al. 2013; Li et al. 2017). This evidence concerns the gene ALK and non-small cell lung carcinoma.